Aptivus Labeling Recommends Genotypic And Liver Function Testing
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for Boehringer Ingelheim's HIV therapy recommends genotypic or phenotypic testing and liver function testing prior to therapy. Aptivus (tipranavir) clears FDA with a "black box" warning on hepatitis and hepatic decompensation and extensive drug-drug interactions.